← Evidence map

ArticleNeurology. Clinical practice2026

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Alireza Atri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. | OpenQuestion